BioSpace News Archive

Access to health insurance for the rideshare labor force is often out of reach. A unique partnership aims to change that.

PHILADELPHIA, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Spark TMS , a leading mental health service provider in Philadelphia, will host their first-ever live demonstration of BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) helmet for the public. Deep TMS is a medication-free, noninvasive treatment used to treat obsessive-compulsive disorder (OCD). The “End OCD Now” demo event will take place on Wednesday, Oct. 16 from 4:30 p.m. to 7:00 p.m., which coincides with OCD Awareness Week

Ultra-sensitive proprietary nanowire technology positioned to provide global physicians with new tool for diagnosis of traumatic brain injury and inflammatory disease

Lux Research Examines Digital Transformation of Global Healthcare Industry Operations

Elamipretide in Phase 3 development for primary mitochondrial myopathy If option is exercised, Alexion & Stealth will co-develop and co-promote subcutaneous elamipretide in U.S. & Alexion will receive exclusive ex-U.S. license

Phynd Technologies, a leading provider information management vendor, announced today a partnership with MedTouch, a leading provider of healthcare strategy, creative, technology, and marketing services, to help health systems provide consumers with convenient and easy access to the precise care they need when they need it

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that Chief Executive Officer, Roger Crystal, M.D., and Chief Scientific Officer, Phil Skolnick, Ph.D., D.Sc. (hon.), will provide an in-depth review of Opiant’s most advanced programs for treating addiction and drug overdose, on Thursday, October 17th in New York City at 12:00 pm ET.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced that clinical data on the Company’s lead product candidate eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3Ig fusion protein based on the LAG-3 immune control mechanism, will be presented at two industry conferences in October and November 2019.

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today named life sciences industry veteran Kevin Buchi chief executive officer of BioSpecifics

Nordion (Canada) Inc., a Sotera Health Company, and Societatea Nationala Nuclearelectrica SA (SNN) of Romania jointly announce an agreement to evaluate the potential commercial production of Cobalt-60 at the Cernavodă Nuclear Power Plant (CNPP).